An interventional study of Shockwave IVL and Shockfast IVL in Coronary Arterial Disease and Calcified Coronary Artery Disease, sponsored by Shunmei Medical. Recruiting at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Shunmei Medical · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 154 studies in Coronary Artery Disease with a site in Poland — 33 open to participants now, 47 under way, 4 of them phase 3. Coronary Artery Disease · Poland.
Among the 154 studies in Coronary Artery Disease with a site in Poland, this one is the 85th largest by planned enrollment of the 114 interventional ones that give a count, is one of 5 that started in 2026, is one of 64 with no phase, reaches primary completion later than 21 of the 46 other live ones, and was the 152nd registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →33 of the 154 studies in Coronary Artery Disease with a site in Poland are open now. Recruiting first, the newest first:
Teleflex · Sites in Poland, United States, France and 1 more country
Ages 18–80
Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o. · Sites in Poland
Ages 18+
Collegium Medicum w Bydgoszczy · Sites in Poland
Ages 18+
Medical University of Bialystok · Sites in Poland
Ages 18–75
Fondazione Ricerca e Innovazione Cardiovascolare ETS · Sites in Poland, Italy, Romania and 1 more country
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
154 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 25 · Phase 4 18
First in 1999; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is close to the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 348 across the 114 interventional studies, 585 across the 40 observational. Of the 91 that completed or were terminated, 23 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 154 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Shunmei Medical as lead sponsor.
Shunmei Medical has 1 study filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Coronary Artery Disease with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03781492Silesian Centre for Heart DiseasesStable Angina Management and Treatment | 2026-12-31 |
| NCT04545112XeltisXeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH) | 2027-02 |
| NCT07078370Vascudyne, Inc.Safety Study of Acellular Tissue Engineered Vessel for Coronary Artery Bypass | 2027-03-30 |
| NCT06451146Regional Cardiology Center, The Copper Health Centre (MCZ),Lower Silesian Orbital Atherectomy Registry (LOAR) | 2027-05-01 |
| NCT07091682Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 154 studies in Coronary Artery Disease with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Coronary artery disease is caused by narrowing of the artery lumen. Treatment with Percutaneous Coronary Intervention (PCI) may be needed. This is a minimally invasive procedure used to treat narrowed or blocked coronary arteries. Sometimes a stent is placed to keep the artery open. If the lesions in the coronary artery are calcified, this may cause difficulties for successful stent placement. The calcified plaques can be fractured via intravascular lithotripsy (IVL) with devices like ShockWave IVL and ShockFast IVL. The aim of this study is to compare the this relatively new ShockFast IVl with the more widely used ShockWave IVL.
Coronary calcified lesions have evolved as one of the most challenging indications for coronary percutaneous interventions (PCI). Different dedicated devices have been recently introduced into the market to improve procedural success in this challenging PCI population. Shockwave Intravascular Lithotripsy, (Shockwave IVL), Shockwave Medical, SC, CA, USA, was the first intracoronary device that used sonic pressure to fracture intracoronary calcium. The device safety and efficacy has been proved in a series of clinical trials. ShockFast intravascular lithotripsy (ShockFast IVL), Shunmei medical, Shenzhen, China, is a new dedicated device to treat intracoronary calcium that makes use of sonic pressure waves to fracture calcified plaques. ShockFast IVL has recently obtained CE mark approval for this indication.
The aim of this study is to compare this new lithotripsy device (ShockFast IVL) with the existing and widely used lithotripsy device that uses the same principle of action, the Shockwave IVL, Shockwave Medical, SC, CA, USA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients aged ≥18 years undergoing PCI for stable or unstable angina or staged procedure after successful treatment of a myocardial infarction where heart enzymes are decreasing
Angiographic criteria:
Severe Calcification:
Target lesion with diameter stenosis ≥70% by visual, or ≥50% with evidence of clinical ischemia
OCT Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Interventional procedure using a dedicated device to treat coronary calcified lesions by offering precise control of sonic pressure waves for safe fracture calcium deposits within the artery walls, thus maintaining vessel flexibility and promoting smoother stent placement. The ShockFast device has an improved crossing profile and 2 lengths of the catheter: 12 and also 15mm compared to ShockWave which has only 1 length.
Device: Shockfast IVL
Interventional procedure that utilizes a fluid-filled catheter connected to an energy source that generates mechanistically tuned ultrasonic acoustic pressure waves - or Shockwaves - for modification, fracture, and fragmentation of vascular calcification.
Device: Shockwave IVL
Treatment of subjects with coronary calcified lesions with an interventional procedure that utilizes a fluid-filled catheter connected to an energy source that generates mechanistically tuned ultrasonic acoustic pressure waves - or Shockwaves - for modification, fracture, and fragmentation of vascular calcification.
Treatment of subjects with coronary calcified lesions with an interventional procedure using a dedicated device to treat coronary calcified lesions by offering precise control of sonic pressure waves for safe fracture calcium deposits within the artery walls, thus maintaining vessel flexibility and promoting smoother stent placement. The ShockFast device has an improved crossing profile and 2 lengths of the catheter: 12 and also 15mm compared to ShockWave which has only 1 length.
Stent area post PCI measured at the minimal lumen area during initial procedure, evaluated by OCT
Time frame: Hospitalisation (during procedure)
Target lesion failure defined as cardiac death, target-vessel myocardial infarction and target-lesion revascularisation at discharge and 30 days
Time frame: 30 day follow-up
Angiographic success
* Defined as a successful stent delivery with diameter of stenosis post PCI of \<50% without severe dissection (type D-F), perforation, abrupt vessel closure or persistent less than Thrombolysis in Myocardial Infarction (TIMI)-3 flow. * By collecting data through angiography and imaging: * Minimal lumen area post stenting * Residual area of stenosis * Residual diameter of stenosis \<30% * Residual diameter of stenosis \<50% * Optical Coherence Tomography (OCT) measured under expansion (\<80% of the reference lumen area) * Post-IVL acute area gain (measured at the minimum lumen area post IVL) * Number of visible calcium cracks post IVL * Severe coronary dissection post IVL (type C-F)
Time frame: Hospitalisation (during procedure)
Device success
Defined as success of the device to cross and fully expand
Time frame: Hospitalisation (during procedure)
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 8 months after the start.
Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 8 months is below that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.